Basic Science: BPH/LUTS
Moderated Poster Session
MP3-6 - Clinical characteristics and gene expression associated with pre-operative prostate volume in patients undergoing holmium enucleation of the prostate (HoLEP) for benign prostatic hyperplasia.
Thursday, September 20
4:00 PM - 6:00 PM
Location: Room 243
Presenting Author(s)
-
Joel Funk, MD FACS
Associate Professor
Division of Urology, University of Arizona College of Medicine
Author(s)
MP
Michael Phung
Urology Resident
Division of Urology, University of Arizona College of Medicine
-
Ken Batai
Division of Urology, University of Arizona College of Medicine
KH
Kieran Hynes
Medical Student
University of Arizona College of Medicine - Division of Urology
KH
Kieran Hynes
Medical Student
University of Arizona College of Medicine - Division of Urology
RB
Robert Bell
Pathology Resident
Department of Pathology, University of Arizona College of Medicine
RB
Robert Bell
Pathology Resident
Department of Pathology, University of Arizona College of Medicine
EB
Erika Bracamonte
Associate Professor, Director of Surgical Pathology
Department of Pathology, University of Arizona College of Medicine
EB
Erika Bracamonte
Associate Professor, Director of Surgical Pathology
Department of Pathology, University of Arizona College of Medicine
EP
Elinora Price
Research Coordinator
University of Arizona College of Medicine - Division of Urology
EP
Elinora Price
Research Coordinator
University of Arizona College of Medicine - Division of Urology
AL
Aye Lwin
Urology Resident
Division of Urology, University of Arizona College of Medicine
AL
Aye Lwin
Urology Resident
Division of Urology, University of Arizona College of Medicine
Introduction & Objective :
Management of benign prostatic hyperplasia (BPH) currently consists of medication or surgery, however, it is not clear which patients will progress from medical therapy to surgical treatment. In order to better understand clinical and molecular characteristics of patients with advanced BPH, we examined patients who underwent holmium enucleation of the prostate (HoLEP) for treatment.
Methods :
Clinical information of patients who underwent HoLEP for treatment of BPH at Banner-University Medical Center Tucson and Banner-University Medical Center South between 2012 and 2015 were reviewed. To examine patient characteristics, logistic and linear regression analysis was performed adjusting for relevant variables. A subset of patients (n=34) without prostate cancer (PCa) were selected for gene expression analysis. RNA was extracted from 1.5mm punches removed from formalin-fixed paraffin-embedded (FFPE) glandular epithelial and stromal tissue samples. RT-PCR was performed to measure expression of two genes, A2M and TGFB3.
Results :
We identified 146 men without prior diagnosis of PCa, final pathological diagnosis of PCa, or undergone a previous surgical prostate reduction procedure. Body mass index (BMI) was positively correlated with pre-operative prostate volume (p=0.03). In linear regression analysis, association between BMI and prostate volume was strong after adjusting for age and race/ethnicity (Beta=0.28, p=0.001). Adjusting for comorbidity (diabetes, hypertension, and hyperlipidemia) did not change the association.
Patients with large pre-operative prostate volume had higher A2M expression compared to patients with smaller volumes (p=0.05) and A2M expression in the stroma was significantly negatively correlated with age at surgery (P=0.006) for Hispanic Americans. In the older patients (age 70 or older), A2M expression in the gland was positively correlated with pre-operative prostate volume (P=0.01), and TGFB3 expression in the gland was positively correlated with BMI (P=0.007). In Hispanic Americans, TGFB3 expression in the stroma was significantly correlated with age at surgery (P=0.02).
Conclusions :
Prostate volume is significantly correlated with BMI as well as A2M and TGFB3 expression in certain patients. Patients with elevated BMI and prostate volume may be at higher risk for failure of medical management and progression to surgical treatment. A2M expression, and TGFB3 expression in Hispanic Americans, were increased in patients with large prostate volumes and may be markers of interest for future studies. Further research is needed to validate the use of BMI as a screening tool and the role of A2M and TGFB3 in the disease process.